⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10432969 | 0.90 | CTSK (0.39) | — | |
| SCHEMBL647137 | 0.85 | CTSK (0.36) | — | |
| SCHEMBL28915190 | 0.80 | — | — | |
| SCHEMBL21726292 | 0.77 | CTSK (0.34) | — | |
| SCHEMBL1543385 | 0.77 | CTSK (0.34) | — | |
| SCHEMBL2106510 | 0.74 | CYP11B2 (0.36) | — | |
| SCHEMBL872168 | 0.72 | — | — | |
| SCHEMBL13354515 | 0.67 | CTSK (0.38) | — | |
| SCHEMBL11634560 | 0.67 | CTSK (0.33) | — | |
| SCHEMBL28575045 | 0.67 | CTSK (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4709481-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20250387400-A1 | TYK2 INHIBITORS | BIOGEN MA INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | RAYTHERA, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-08-21 | — | — | US | disclosed |
| WO-2025137267-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4547674-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250127795-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | UCB Biopharma SRL (BE) | 2025-04-24 | — | — | US | disclosed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014065791-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | disclosed |
| EP-2288610-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |